Andere Sprachen Merck & Co., Inc.

Aktien

A0YD8Q

US58933Y1055

MRK

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:31:50 30.11.2023			% 5 Tage	% 1. Jan.
101,87 ^USD	+0,73%		+0,27%	-7,94%

12:00	Acclinate arbeitet mit Merck zusammen, um die Diversität bei klinischen Studien zu erhöhen	CI
29.11.	Doubleverify Holdings Insider verkaufte Aktien im Wert von $56,765,625, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Schalten Sie alle Nachrichten zu allen Unternehmen frei: Verpassen Sie keine profitable Investitionsmöglichkeit mehr!

100% kostenlose Registrierung

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity	12:00
Doubleverify Holdings Insider Sold Shares Worth $56,765,625, According to a Recent SEC Filing	29.11.
Merck's V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older	29.11.
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development	29.11.
Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023	28.11.
Merck Raises Quarterly Dividend to $0.77 Per Share; Payable Jan. 8 to Shareholders of Record on Dec. 15	28.11.
Merck Raises Quarterly Dividend 5.5% To 77 Cents	28.11.
Merck Announces First-Quarter 2024 Dividend	28.11.
Merck Declares Dividend for the First Quarter of 2024, Payable on January 8, 2024	28.11.
Merck : résultats prometteurs pour le vaccin pneumococcique	28.11.
Merck Says Phase 3 Trial of Pneumococcal Disease Vaccine Candidate V116 Showed 'Strong Evidence' of Immunogenicity	28.11.
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older	28.11.
Merck Announces Results from STRIDE-3, a Phase 3 Trial Evaluating V116	28.11.
Anaplastic Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23.11.
Hipgnosis Songs, founder Mercuriadis face legal claims	23.11.
US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing	21.11.
Johnson & Johnson, Merck, Bristol Myers Squibb Invited to Testify to Senate Health Committee on Drug Prices	21.11.
Pharma CEOs Asked by Senate to Testify on 'Outrageously' High Prices of Prescription Drugs on Jan. 25	21.11.
Merck : accord en vue d'un rachat de Caraway Therapeutics	21.11.
Merck to Acquire Caraway Therapeutics for Up To $610 Million	21.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Merck & Co, Inc: Eine Cash Cow mit versteckten Erfolgsprodukten

Am 18. Juli 2022 um 17:32 Uhr